| Market Cap | ₹757.87 CrPharmaceuticals |
|---|---|
| 1-Year Return | 101.92%Price Performance |
| Qtr Revenue Growth | 31.25%Year-on-Year |
| P/E Ratio | 205.05Sector PE 45.28 |
| Order from | Therapeutic Goods Administration (TGA), Australia |
Key highlights
- Certification issued by Australia’s Therapeutic Goods Administration (TGA) on October 15, 2026
- Covers the manufacturing facility at B-21/22, MIDC Area, Kalmeshwar, Nagpur, Maharashtra
- Validity extends until June 21, 2028, subject to scheduled TGA re-inspections
- Includes non-sterile finished products like soluble films, wafers, tablets, and capsules
- Complies with PIC/S Guide to Good Manufacturing Practice dated August 25, 2023
Strategic Certification for the Nagpur Facility
Zim Laboratories Limited has achieved a significant regulatory milestone with its Nagpur-based manufacturing facility receiving the Certificate of Good Manufacturing Practice (GMP) Compliance from Australia's Therapeutic Goods Administration (TGA). Issued on October 15, 2026, the certification follows a rigorous on-site inspection conducted in April 2026. This approval confirms that the facility at MIDC Area, Kalmeshwar, complies with the PIC/S Guide to Good Manufacturing Practice for Medicinal Products.
Valid until June 21, 2028, the certification covers the manufacture of non-sterile finished products across both registered and listed therapeutic goods categories, marking a critical step for the company's international operational standards.
Certified Dosage Forms and Technical Scope
- Hard capsules and solid unit dosage forms for diverse therapeutic segments
- Pharmaceutical tablets and granules including powders for suspension
- Innovative oral thin films and soluble films using proprietary technology
- Medicinal wafers for enhanced patient convenience and treatment adherence
- Non-sterile finished products for both registered and listed categories
- Compliance with the latest PIC/S Guide requirements from August 2023
Expanding Global Market Footprint
The TGA certification is expected to serve as a catalyst for Zim Laboratories' expansion into the Australian market and other Rest of World (RoW) jurisdictions. By securing GMP evidence from a high-stringency regulator like the TGA, the company strengthens its credentials for regulatory submissions in countries that accept or rely on Australian inspection outcomes. This follows a string of international successes, including marketing authorizations from the Italian Medicines Agency (AIFA) in May 2026 and Portugal's INFARMED in March 2025.
These regulatory milestones provide a foundation for developing manufacturing partnerships and pursuing global product-specific approvals for their differentiated generic product portfolio.
Financial Performance and Recent Trajectory
Financially, Zim Laboratories reported an operating revenue of ₹94.18 crore for the quarter ended June 30, 2026, representing a 31.25% growth compared to the same period last year, although the company faced a net loss of ₹4.02 crore during the same period. The current operating profit margin stands at 2.6%. With a market capitalization of ₹757.87 crore, the company has seen its stock price double over the last year.
The upcoming board meeting scheduled for November 3, 2026, to approve Q2 FY27 results will be a key indicator for tracking the company's progress toward profitability following these new regulatory clearances.
| Date | Announcement | Amount |
|---|---|---|
| 19 May 2026 | Marketing Authorization granted by Italian Medicines Agency (AIFA) for Dabigatran Etexilate hard capsules (75 mg, 110 mg & 150 mg) in Italy via DCPSource: sihl.in | – |
| 03 Dec 2025 | CDSCO approval to manufacture and market Fixed Dose Combination of Naproxen Delayed Release and Esomeprazole Capsules (375mg/500mg + 20mg/20mg) in IndiaSource: BSE filing | – |
| 08 Aug 2025 | Marketing Authorization granted by Australia's Therapeutic Goods Administration (TGA) for Tamsulosin Hydrochloride and Dutasteride CapsulesSource: indianpharmapost.com | – |
| 21 Jul 2025 | Marketing Authorization granted by Australia's Therapeutic Goods Administration (TGA) for Rizatriptan Benzoate Orally Disintegrating Films in AustraliaSource: NSE filing | – |
| 19 Mar 2025 | Marketing Authorization granted by Portugal's INFARMED for Dimethyl Fumarate (120 mg & 240 mg) Modified Release CapsulesSource: NSE filing | – |
| 10 Jan 2025 | Marketing Authorization granted in Europe by CHMP to partner Neuraxpharm for co-developed Buprenorphine Sublingual FilmSource: neuraxpharm.com | – |
What to watch next
- Board meeting to approve Q2 FY27 financial results on November 03, 2026
- Development of manufacturing partnerships in the Australian market following GMP certification
- Regulatory submissions in Rest of World (RoW) markets leveraging TGA inspection outcomes
| Share price | ₹141.24 |
|---|---|
| Market capitalisation | ₹757.87 Cr |
| Revenue (annual) | ₹374.40 Cr |
| Net profit (annual) | ₹5.84 Cr |
| Revenue (latest quarter) | ₹94.18 Cr-10.54% vs previous quarter |
| Net profit (latest quarter) | -₹4.02 Cr-207.41% vs previous quarter |
| P/E (TTM) | 205.05×Sector 45.28× |
| Promoter holding | 30.3%-0.06% QoQ |
| FII holding | 0.17%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Zim Laboratories Limited announcing the receipt of TGA GMP Certification from Australia. Market figures from a third-party data provider.
Track Zim Laboratories live
Get the next Zim Laboratories filing on Telegram seconds after it lands. 15 days free.
